Edition:
United Kingdom

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

1.45USD
15 Dec 2017
Change (% chg)

$0.10 (+7.41%)
Prev Close
$1.35
Open
$1.35
Day's High
$1.45
Day's Low
$1.35
Volume
13,790
Avg. Vol
16,575
52-wk High
$3.00
52-wk Low
$1.05

Chart for

About

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical... (more)
No analyst recommendations are available for .

Overall

Beta: 1.86
Market Cap(Mil.): $19.46
Shares Outstanding(Mil.): 12.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Arca Biopharma announces issuance of European patent on cardiovascular disease treatment methods

* Arca Biopharma announces issuance of European patent for treating cardiovascular diseases and conditions with a new chemical entity utilizing genetic targeting

16 Nov 2017

BRIEF-ARCA Biopharma announces third quarter financial results

* ARCA Biopharma announces third quarter 2017 financial results and provides business update

09 Nov 2017

BRIEF-ARCA Biopharma to share top-line results in Q1 next year for GENETIC-AF trial​

* ARCA Biopharma announces GENETIC-AF data and safety monitoring board recommendation to complete Phase 2B GENETIC-AF clinical trial based on efficacy and safety data in phase 2b interim analysis

09 Aug 2017

BRIEF-Arca Biopharma Q2 loss per share $0.59

* Arca Biopharma announces second quarter 2017 financial results and provides business update

03 Aug 2017

BRIEF-ARCA Biopharma announces database lock for genetic-af phase 2b interim efficacy analysis

* ARCA Biopharma announces database lock for genetic-af phase 2b interim efficacy analysis – dsmb recommendation anticipated in august 2017 Source text for Eikon: Further company coverage:

20 Jun 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $37.20 +0.74
Novartis AG (NOVN.S) CHF83.80 -0.05
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Abbott Laboratories (ABT.N) $55.50 +0.77
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.55 -0.22
Eli Lilly and Co (LLY.N) $86.54 +0.04

Earnings vs. Estimates